Peter Barton Hutt is a partner specializing in food
and drug law in the Washington, D.C. law firm of Covington
& Burling. He served as Chief Counsel for the FDA
from 1971-1975 and is the co-author of a casebook used
to teach food and drug law throughout the country.
Mr. Hutt currently serves on the Boards of Directors
of several public and privately-held biotechnology companies,
including CV Therapeutics and Pervasis Therapeutics.
He has previously served as a director of other companies,
including IDEC Pharmaceuticals Corporation (now Biogen
IDEC Inc.) during its development of Rituxan®. Mr.
Hutt has served on many advisory committees including
the Advisory Committee to the Director of the National
Institutes of Health (NIH), the NIH Advisory Committee
to Review the Guidelines for Recombinant DNA Research,
and five Office of Technology Assessment advisory panels.
Washingtonian magazine has named Mr. Hutt one of Washington
D.C.'s 50 best lawyers (out of more than 40,000) and
one of Washington D.C.'s 100 most influential people.
The National Law Journal has named him one of the 40
best health care lawyers in the United States and the
European Counsel has called him the best FDA regulatory
specialist in Washington, D.C.
Mr. Hutt graduated from Yale University and Harvard
Law School and earned a Master of Laws degree in Food
and Drug Law from New York University Law School.
|
